Natera presents Signatera data at ASTRO, shows utility in multiple cancers

Natera (NTRA) presented four oral abstracts at ASTRO 2026, its first participation at the radiation oncology conference. Signatera demonstrated high sensitivity and specificity for recurrence detection in locally advanced rectal cancer, identified high-risk groups in anal cancer, and showed utility in vulvovaginal and cervical cancers. The data supports Signatera's role in treatment response monitoring and risk stratification for radiation oncologists.